ArticleFrontiers in microbiology2020
Evaluation of the Clinical Systems for Polymyxin Susceptibility Testing of Clinical Gram-Negative Bacteria in China.
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 22 citations in OpenAlex.
- Overexpression of endogenous aldehyde:ferredoxin oxidoreductase genes enhances ethanol biosynthesis in Clostridium autoethanogenum.World journal of microbiology & biotechnology · 2026Article
- The Role of Akkermansia muciniphila in Obesity: Benefit or Harm?Probiotics and antimicrobial proteins · 2026Review
- Mapping the resistance landscape: A large-scale study of polymyxin-resistant pathogens circulating in low-and middle-income countries.Research square · 2026Article
- Colistin Resistance inAntibiotics (Basel, Switzerland) · 2026Article
- CRISPR/Cas9 in perspective: evaluating efficacy, delivery methods, and ethical challenges in genome editing.Molecular biology reports · 2026Review
- Quorum sensing disruption in Enterobacter spp.: unlocking new therapeutic pathways against multidrug-resistant infections.Antonie van Leeuwenhoek · 2026Review
- Breaking resistance: strategies for novel antibacterial therapeutic interventions.Molecular biology reports · 2026Review
- Association of polymyxin B MIC with pharmacokinetic/pharmacodynamic target attainment and clinical outcomes in carbapenem-resistant enterobacterales infections.Frontiers in pharmacology · 2026Article
- Understanding phage Receptor-binding protein interaction with host surface receptor: the key for phage-Mediated detection and elimination of Pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
- Genomic Features of E. ruysiae Associated with the Ecological Origin: Implications for the Environmental Hypothesis.Current microbiology · 2025Article
- Changes in root-associated bacterial communities across growth stages of salt-tolerant and salt-sensitive rice grown in coastal saline-alkali soils.World journal of microbiology & biotechnology · 2025Article
- Mechanisms, therapeutic strategies, and emerging therapeutic alternatives for carbapenem resistance in Gram-negative bacteria.Archives of microbiology · 2025Review
- Challenges in the Detection of Polymyxin Resistance: From Today to the Future.Microorganisms · 2024Review
- Antimicrobial Peptide MPX with Broad-Spectrum Bactericidal Activity Promotes Proper Abscess Formation and Relieves Skin Inflammation.Probiotics and antimicrobial proteins · 2023Article
- DNA supercoiling and regulation of intrinsic β-lactamase in pathogenic Escherichia coli.Archives of microbiology · 2023Review
- Evaluation of Commercial Products for Colistin and Polymyxin B Susceptibility Testing forInfection and drug resistance · 2023Article
- Evaluation of polymyxin B AUC/MIC ratio for dose optimization in patients with carbapenem-resistantFrontiers in microbiology · 2023Article
- Disease-associated dysbiosis and potential therapeutic role of Akkermansia muciniphila, a mucus degrading bacteria of gut microbiome.Folia microbiologica · 2022Review
- What makes another life possible in bacteria? Global regulators as architects of bacterial biofilms.World journal of microbiology & biotechnology · 2022Review
- Isolation and characterization of human anti-CD20 single-chain variable fragment (scFv) from a Naive human scFv library.Medical oncology (Northwood, London, England) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe performance of mainstream commercial antimicrobial susceptibility testing systems on polymyxins has not been well evaluated in China. In this study, three antimicrobial susceptibility testing systems were evaluated for polymyxin B and colistin.
methodsThe MICs of 257 Gram-negative strains collected from clinical cases and livestock were determined and analyzed. Using Broth Microdilution as the gold standard, the performance of VITEK 2
resultsThe EA, CA, VME, and ME to polymyxin B for Bio-kont were 83.5, 95.6, 13.1, and 0.6%, respectively. The EAs, CAs, VMEs, and MEs to colistin were as follows: Bio-kont, 86.7%/96.5%/7.2%/1.7%; Vitek 2, 64.2%/86.8%/41.0%/0%, and Phoenix M50, 92.9%/92.9%/21.7%/0%. The performance of Bio-kont to polymyxin B and colistin for
conclusionWith relatively more accurate results for polymyxin B and colistin and lower VME, Bio-kont has an advantage in polymyxin antimicrobial susceptibility testing, especially for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.